HK Stock Market Move | QYUNS-B(02509) is now up more than 6% and QX001S has obtained a drug registration certificate issued by the State Food and Drug Administration.

QYUNS-B (02509) rose nearly 20% in the afternoon, and as of the time of writing, rose 6.23% to 8.87 Hong Kong dollars. On the news front, Trinomabio announced that on November 5, Zhongmei Huadong received the Drug Registration Certificate issued by the National Medical Products Administration (NMPA) for the registration of the listing application of ustekinumab injection (trade name: Silesin, research and development code: QX001S/HDM3001) applied by Zhongmei Huadong, approved for the treatment of moderate to severe plaque psoriasis in adults. It is reported that QX001S was originally independently developed by Trinomabio. In August 2020, the company entered into a cooperation agreement with Zhongmei Huadong to jointly advance the Phase III clinical trial of QX001S. Zhongmei Huadong, as the holder of the market authorization, is responsible for commercialization in mainland China, while Sifus is responsible for product production and supply. QX001S is the first product in Trinomabio's research pipeline to be approved for marketing, and also the first approved ustekinumab injection biosimilar in China.